• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Aflibercept monotherapy equivalent to bevacizumab first for diabetic macular edema

byNhat Hung (Benjamin) LamandKiera Liblik
August 29, 2022
in Chronic Disease, Endocrinology, Ophthalmology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with diabetic macular edema, aflibercept monotherapy showed no difference in vision improvement compared to step therapy of bevacizumab first followed by a switch to aflibercept.

2. Serious adverse events were more common in aflibercept monotherapy group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Diabetic macular edema is a leading cause of vision loss. Standard of care for this condition includes intravitreous anti-vascular endothelial growth factor (anti-VEGF) agents. Aflibercept is Food and Drug Administration-approved specifically for diabetic macular edema. However, bevacizumab is a lower-cost anti-VEGF agent which can be used off-label for this indication. While aflibercept has been shown to be more effective than bevacizumab, its superiority to a step therapy of bevacizumab first followed by a switch to aflibercept if required has not been previously evaluated. The present study was a multicenter, randomized trial to compare these two regimens in patients with moderate vision loss due to macular edema. At two years, 70% of the eyes under step-therapy were switched to aflibercept. There was no difference between aflibercept monotherapy and step-therapy in the improvement of visual acuity and retinal findings. Serious adverse events and hospitalizations were more common in the aflibercept monotherapy group. Although the generalizability of the study results is limited in that Asians, Native Americans, and Alaska Natives were underrepresented.

Click here to read the study in NEJM

Relevant Reading: Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

In-Depth [randomized controlled trial]: The current study was a multicenter, randomized, controlled trial conducted at 54 sites across the United States to compare aflibercept monotherapy and bevacizumab first step therapy. Adult patients were included if they had type one or two diabetes, at least one eye with a best-corrected Electronic Early Treatment Diabetic Retinopathy Study visual acuity letter score of 24 to 69, and centrally involved diabetic macular edema on ophthalmoscopy. Eyes treated with anti-VEGF therapy for diabetic macular edema in the preceding 12 months or any treatment for diabetic macular edema in the preceding four months were excluded. A total of 270 patients were randomized 1:1 to receive 2mg intravitreous aflibercept monotherapy or 1.25mg intravitreous bevacizumab followed by a switch to 2mg aflibercept if the treated eye showed an unsatisfactory response. The primary outcome was visual-acuity letter score change over 104 weeks. Overall, the mean improvement in visual acuity was 15.0 letters in the aflibercept-monotherapy group and 14.0 letters in the bevacizumab-first group (Adjusted Difference, 0.8 letters; 95% Confidence Interval [CI], -.0.9 to 2.5; p=0.37). Retinal findings were also similar between the groups. At 104 days, 70% of the eyes in the step therapy group switched from bevacizumab to aflibercept therapy. Endophthalmitis occurred in one eye treated with aflibercept monotherapy. Systemic serious adverse events (52% of patients on aflibercept monotherapy; 36% of patients on bevacizumab first therapy) and hospitalizations (in 48% and 32%, respectively) were more prevalent among patients on aflibercept monotherapy. Overall, aflibercept monotherapy did not provide superior improvements in macular edema patients over bevacizumab first therapy.

RELATED REPORTS

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: afliberceptbevacizumabchronic diseasediabetic macular edemaendocrinologymacular edemaOphthalmologytype 1 diabetestype 2 diabetes
Previous Post

Characteristics of monkeypox virus infections across 16 countries

Next Post

Tailored care approaches may improve glaucoma medication adherence

RelatedReports

β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

January 27, 2023
Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

January 27, 2023
2 Minute Medicine Rewind May 20, 2019
Chronic Disease

Chronic obstructive pulmonary disease associated with worse postoperative outcomes

January 26, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
Next Post
ACGME duty hour regulations linked with decreased perceived quality of care

Tailored care approaches may improve glaucoma medication adherence

Age and breast cancer risk factors associated with false-positive mammography results

Increased breast cancer mortality observed in black women in the United States

Hamstring tendons often regenerate after harvest for ACL repair

Surgical reconstruction is superior to non-surgical rehabilitation for non-acute anterior cruciate ligament tears

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Community-based adult vision screening program increases access to eye care
  • Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options